Matthew Ku

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar et al. · The Lancet Oncology · 2022 · 390 citations

Lymphoid Neoplasia, Bispecific Antibody, Medicine +7

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J. Schuster, Nancy L. Bartlett, Sarit Assouline et al. · Blood · 2019 · 179 citations

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Jeremy S. Abramson, Matthew Ku, Mark P. Hertzberg et al. · The Lancet · 2024 · 114 citations

Hematological Malignancy, Open-label Trial, Lymphoid Neoplasia +8

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine S. Tam, Andrew Grigg, Stephen Opat et al. · Blood · 2015 · 111 citations

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Nicole Wong Doo, Carole Soussain, Sylvain Choquet et al. · UCL Discovery (University College London) · 2022 · 76 citations